艾托格列净在制备治疗或改善孤独症药物中的应用
By using etagliflozin to inhibit oxidative stress and inflammation, the problem of diversity and lack of relevance in autism treatment has been addressed, significantly improving social impairment, repetitive stereotypes, and anxiety-like behaviors, providing a new drug treatment option for autism.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 河南省儿童医院郑州儿童医院
- Filing Date
- 2025-08-20
- Publication Date
- 2026-07-17
AI Technical Summary
Current technology lacks effective medications for treating autism, especially for symptoms such as social impairment, repetitive and stereotyped behaviors, and anxiety-like behaviors, and treatment methods lack uniformity and coherence.
Using etagliflozin as a sodium-glucose cotransporter 2 inhibitor, various drug formulations such as tablets and capsules have been developed to treat autism by inhibiting oxidative stress, inflammatory responses, and excessive activation of microglia in the prefrontal cortex and hippocampus.
Etoggliflozin significantly improved impaired social skills, reduced repetitive stereotyped and anxiety-like behaviors, and decreased oxidative stress and inflammation levels in BTBR mice, offering new potential for the treatment of autism.
Smart Images
Figure CN120837482B_ABST